Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HCEEF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
RG-6148
|
|||||
| Synonyms |
DHES-0815A; RG 6148; DHES 0815A; RG6148; DHES0815A
Click to Show/Hide
|
|||||
| Organization |
Genentech, Inc.; Roche Holding AG
|
|||||
| Drug Status |
Terminated in phase 1
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
MHES0488A
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Pyrrolo[2,1-c][1,4]benzodiazepine monoamide (PBD-MA)
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Methyl-disulfide linker
|
Linker Info | ||||
| Conjugate Type |
Site-specific conjugation through the engineered cysteine (THIOMAB,LC-Cys149).
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.